Physician profile
Annais Troncoso
NPI 1568050169
$2,559.16
in general payments reported to CMS, 2019-2025
29 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $398 · 2023: $249 · 2024: $481 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $413.63 | 2025 | Senza, Vyrsa V1, Omnia |
| Mdd US Operations, LLC | $322.56 | 2023-2025 | Gocovri, Gocovri, Apokyn |
| Corcept Therapeutics | $239.98 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $204.45 | 2023-2025 | Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $192.59 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $187.14 | 2021-2025 | Airsupra |
| Abbvie INC. | $167.08 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $124.58 | 2021-2024 | Nuplazid |
| Biogen, INC. | $76.61 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Otsuka America Pharmaceutical, INC. | $75.18 | 2024-2025 | Rexulti |
| Neurelis, INC. | $66.53 | 2021-2023 | Valtoco |
| Shield Therapeutics INC | $59.02 | 2025 | |
| Pfizer INC. | $48.01 | 2023-2025 | |
| Stimwave Technologies Incorporated | $47.11 | 2022 | |
| Eisai INC. | $41.60 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $35.62 | 2025 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.26 | 2025 | Jardiance |
| Amgen INC. | $29.33 | 2022-2024 | Prolia, Evenity |
| Amneal Pharmaceuticals LLC | $25.44 | 2024 | Rytary |
| Xeris Pharmaceuticals, INC. | $22.63 | 2025 | Recorlev |
| Corium, LLC | $21.96 | 2022 | |
| Nevro Corp. | $20.84 | 2024 | Senza |
| Seqirus USA INC | $18.74 | 2025 | Flucelvax, Fluad |
| Ucb, INC. | $18.02 | 2024 | Zilbrysq |
| Sumitomo Pharma America, INC. | $15.32 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $14.75 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.59 | 2025 | Spravato |
| Tandem Diabetes Care, INC. | $13.91 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Spr Therapeutics, INC | $11.68 | 2025 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annais Troncoso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.